Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

Completed · Phase 1 · Has a placebo group

Conditions studied: Hypertriglyceridemia

In brief

The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation

Key facts

Study ID

NCT01133210

Run by

Washington University School of Medicine

People needed

27

Starts

2011-01-01

Expected to finish

2012-11-01

Last updated by the study team

2013-12-10

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• obese (body mass index (BMI) between 30 and 45.9)
• increased plasma triglyceride concentrations (150-400 mg/dL)

You may not qualify if…

• active or previous infection with hepatitis B or C
• history of alcohol abuse
• current alcohol consumption (>20g/day)
• severe hypertriglyceridemia (>400 mg/dL)
• active peptic ulcer disease
• diabetes
• pregnant or lactating
• take statins, fibrates, niacin, moderate to strong Cyp3A4 inhibitors or inducers, or any other medication that might confound interpretation of the study results will be excluded.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.